Research advances in central serous chorioretinopathy

Central serous chorioretinopathy (CSC) predominantly affects males aged 20 to 50.It is characterized by serous neurosensory retinal detachment.CSC can be classified as acute (self-limiting) or chronic (lasting ≥3 months) types.Complications of chronic CSC include choroidal neovascularization and retinal pigment epithelium (RPE) atrophy, which can lead to irreversible vision damage.Studies have found that the onset of CSC is associated with genetic predisposition (e.g., CFH and NR3C2 gene loci), exposure to corticosteroid, endocrine disorders, elevated androgen levels, and psychological stress.Pathological changes center on choroidal thickening and venous overload, manifesting as vortex vein anastomosis and choroidal capillary attenuation.These changes subsequently lead to RPE dysfunction.Multimodal imaging reveals characteristic changes: fundus autofluorescence displays gravity-dependent granular fluorescence signals, while optical coherence tomography indicates damage to the ellipsoid zone and shortening of photoreceptor outer segments, both of which are significantly correlated with visual prognosis.Evidence-based treatment indicates that half-dose photodynamic therapy provides the most advantages in terms of anatomical reattachment and visual improvement.However, the efficacy of micropulse laser and mineralocorticoid receptor antagonists requires validation through large-sample studies.Further exploration of gene-environment interaction mechanisms and targeted treatment strategies is necessary in the future.This article reviews research advances in CSC.

KEYWORDS：

Authors Info & Affiliations